| Literature DB >> 36200522 |
Crisann Moon1, Amber M Gallegos1, Bilal Sheikh1, Pratap Kumar2,3, Michael Liss2,3, Darpan I Patel1,3,4.
Abstract
OBJECTIVES: This study aimed to demonstrate potential translation of pre-clinical studies to a home-based exercise intervention in mediating inflammatory cytokine markers and tumor progression in men under active surveillance for prostate cancer.Entities:
Keywords: active surveillance; biomarker; exercise; prostate cancer; quality of life
Mesh:
Substances:
Year: 2022 PMID: 36200522 PMCID: PMC9549098 DOI: 10.1177/10732748221130964
Source DB: PubMed Journal: Cancer Control ISSN: 1073-2748 Impact factor: 2.339
Figure 1.Study flow diagram.
Inclusion and Exclusion Criteria.
| Inclusion criteria | Exclusion criteria |
|---|---|
| Men >40 years old | Severe cardiac disease (NYHA class III or greater) |
| Diagnosed prostate cancer | Angina |
| Under active surveillance at time of study | Severe osteoporosis |
| Gleason score of 3+3 | Uncontrolled hypertension (>160/95 mmHg) |
| Able to provide consent for study participation | Uncontrolled sinus tachycardia (>120 bpm) |
| Cardiac comorbidities | |
| Uncontrolled diabetes | |
| Uncontrolled pain | |
| Cognitive impairment | |
| History of falls due to balance impairment | |
| Severe neuromusculoskeletal conditions that would prevent walking exercise |
Study Demographics.
| Characteristic | Exercise intervention | Control group | |
|---|---|---|---|
| Age (years) | 72.78 ± 5.31 | 75.17 ± 11.44 | .30 |
| Weight (kg) | 86.56 ± 6.37 | 86.00 ± 7.59 | .44 |
| BMI (kg/m2) | 26.82 ± 2.80 | 28.27 ± 2.52 | .41 |
| Race | |||
| White | 4 | 5 | |
| Black | 3 | 0 | |
| Hispanic | 2 | 1 | |
Inflammatory Cytokine Comparison.
| Within group | ||||||||
|---|---|---|---|---|---|---|---|---|
| Intervention group | Control group | |||||||
| Baseline | End of study | Baseline | End of study | |||||
| Eotaxin | 118.21± 90.30 | 110.22 ± 97.24 | .35 | .13 | 185.41 ± 237.22 | 220.07 ± 283.51 | .16 | −.60 |
| INF-γ | 152.88 ± 312.71 | 118.93 ± 258.79 | .08 | .52 | 255.86 ± 474.23 | 317.32 ± 572.35 | .15 | −.62 |
| IL-12 | 28.69 ± 32.06 | 23.92 ± 19.38 | .16 | .36 | 24.06 ± 27.06 | 23.95 ± 24.64 | .48 | .03 |
| IL-1α | 78.76 ± 183.30 | 65.55 ± 146.70 | .16 | .35 | 332.15 ± 656.77 | 255.12 ± 502.09 | .20 | .50 |
| IL-5 | 18.07 ± 40.84 | 16.82 ± 37.65 | .15 | .38 | 151.60 ± 300.39 | 184.47 ± 366.36 | .20 | −.50 |
| IL-6 | 23.68 ± 45.66 | 21.24 ± 45.18 | .19 | .31 | 95.27 ± 188.89 | 104.98 ± 207.91 | .19 | −.51 |
| TNF-α | 24.58 ± 35.40 | 19.71 ± 20.76 | .21 | .29 | 29.52 ± 41.41 | 32.32 ± 42.24 | .13 | −.68 |
| VEGF | 125.16 ± 198.66 | 80.29 ± 124.30 | .06 | .59 | 115.48 ± 213.25 | 155.80 ± 287.54 | .18 | −.54 |
| Intervention versus control | ||||||||
| Baseline | End of study | |||||||
| Intervention | Control | Intervention | Control | |||||
| Eotaxin | 118.21 ± 90.32 | 185.41 ± 237.22 | .23 | −.46 | 110.22 ± 97.24 | 220.07 ± 283.51 | .25 | −.65 |
| INF-γ | 152.88 ± 312.71 | 255.86 ± 474.23 | .32 | −.28 | 118.93 ± 258.79 | 317.32 ± 572.35 | .20 | −.53 |
| IL-12 | 28.69 ± 32.06 | 24.06 ± 27.06 | .40 | .15 | 23.92 ± 19.38 | 23.95 ± 24.64 | .50 | −.002 |
| IL-1α | 78.76 ± 183.30 | 332.15 ± 656.77 | .25 | −.67 | 65.55 ± 146.70 | 255.12 ± 502.09 | .25 | −.65 |
| IL-5 | 18.07 ± 40.84 | 151.60 ± 300.39 | .22 | −.83 | 16.82 ± 37.65 | 184.47 ± 366.36 | .21 | −.86 |
| IL-6 | 23.68 ± 45.66 | 95.27 ± 188.89 | .25 | −.68 | 21.24 ± 45.18 | 104.98 ± 207.91 | .24 | −.73 |
| TNF-α | 24.58 ± 35.40 | 29.52 ± 41.41 | .42 | −.13 | 19.71 ± 20.76 | 32.32 ± 42.24 | .24 | −.45 |
| VEGF | 125.16 ± 198.67 | 115.48 ± 213.25 | .47 | −.05 | 80.29 ± 124.30 | 155.80 ± 287.54 | .25 | −.41 |
INF-γ = interferon- γ, IL-12 = interleukin-12, IL-α = interleukin- α, IL-5 = interleukin-5, IL-6 = interleukin-6, TNF-α = tumor necrosis factor- α, VEGF = vascular endothelial growth factor.
Health-Related Quality of Life Within Group Comparisons from Baseline to End of Study.
| FACIT-F | ||||||||
|---|---|---|---|---|---|---|---|---|
| Intervention group | Control group | |||||||
| Baseline | End of study | Baseline | End of study | |||||
| PWB | 26.0 ± 1.9 | 24.4 ± 3.4 | .04 | 1.06 | 23.7 ± 5.3 | 24.2 ± 3.1 | .31 | −.21 |
| SWB | 20.0 ± 6.6 | 17.2 ± 7.0 | .07 | .80 | 19.7 ±7.7 | 22.1 ± 7.5 | .08 | −.66 |
| EWB | 23.0 ± 1.0 | 18.8 ± 3.6 | .04 | 1.06 | 21.0 ± 4.2 | 20.7 ± 3.2 | .42 | .09 |
| FWB | 20.8 ± 5.5 | 19.2 ± 8.5 | .25 | .33 | 24.1 ± 7.5 | 24.7 ± 4.5 | .40 | −.11 |
| Fatigue | 45.2 ± 4.9 | 40.8 ± 11.0 | .11 | .66 | 40.5 ± 9.1 | 42.3 ± 10.2 | .10 | −.61 |
| Composite | 135.0 ± 17.1 | 120.4 ± 30.3 | .05 | .99 | 129.0 ± 32.1 | 133.9 ± 26.5 | .20 | −.38 |
| SF-36 | ||||||||
| Intervention group | Control group | |||||||
| Baseline | End of study | Baseline | End of study | |||||
| PF | 84.2 ± 15.9 | 85.0 ± 18.4 | .43 | −.07 | 65.8 ± 23.1 | 84.2 ± 19.6 | .005 | −1.63 |
| RLPH | 37.5 ± 49.4 | 50.0 ± 54.8 | .18 | −.41 | 20.8 ± 40.1 | 58.3 ± 46.6 | .08 | −.69 |
| RLEH | 41.7 ± 32.9 | 66.7 ± 42.2 | .10 | −.60 | 58.3 ± 41.8 | 83.3 ± 40.8 | .06 | −.76 |
| EF | 69.2 ± 15.3 | 65.0 ± 30.7 | .10 | .21 | 52.5 ± 30.3 | 59.2 ± 22.0 | .07 | −.72 |
| EMWB | 88.0 ± 11.3 | 82.0 ± 13.1 | .31 | .52 | 82.7 ± 14.9 | 80.7 ± 22.3 | .29 | .24 |
| SFUN | 87.5 ± 7.9 | 79.2 ± 24.6 | .13 | .36 | 85.4 ± 24.3 | 81.3 ± 29.3 | .09 | .65 |
| Pain | 75.8 ± 26.5 | 69.2 ± 27.5 | .17 | .43 | 77.1 ± 21.4 | 79.2 ± 19.6 | .38 | −.13 |
| GH | 83.3 ± 8.8 | 72.5 ± 18.1 | .09 | .65 | 80.0 ± 11.0 | 78.3 ± 17.8 | .33 | .19 |
PWB = physical wellbeing, SWB = social/family wellbeing, EWB = emotional wellbeing, FWB = functional wellbeing. For SF36: PF = physical functioning, RLPH = role limitations-physical health, RLEH = role limitations-emotional health, EF = energy/fatigue, EMWB = emotional wellbeing, SFUN = social functioning, GH = general health. Higher scores on all scales indicate higher functioning.
Comparison of Exercise Intervention on Fatigue and Quality of Life.
| FACIT-F | ||||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | End of study | |||||||
| Intervention | Control | Intervention | Control | |||||
| PWB | 25.0 ± 3.5 | 23.8 ± 4.1 | .21 | .09 | 24.83 ± 3.2 | 24.17 ± 3.1 | .36 | −.12 |
| SWB | 21.6 ± 6.8 | 21.1 ± 5.8 | .42 | −.32 | 18.67 ± 7.2 | 22.11 ± 7.5 | .22 | −1.19 |
| EWB | 21.8 ± 2.9 | 20.7 ± 3.5 | .19 | .00 | 19.33 ± 3.5 | 20.67 ± 3.2 | .25 | −.98 |
| FWB | 22.6 ± 5.2 | 23.1 ± 6.4 | .43 | −1.06 | 20.17 ± 7.9 | 24.67 ± 4.5 | .13 | −1.06 |
| Fatigue | 44.8 ± 5.7 | 40.9 ± 7.4 | .07 | .13 | 42.67 ± 10.8 | 42.33 ± 10.2 | .48 | −.51 |
| Composite | 135.8 ± 20.5 | 129.5 ± 24.9 | .24 | −.41 | 125.67 ± 30.1 | 133.94 ± 26.5 | .31 | −.89 |
| SF-36 | ||||||||
| Baseline | End of study | |||||||
| Intervention | Control | Intervention | Control | |||||
| PF | 83.3 ± 14.8 | 70.0 ± 21.2 | .03 | .85 | 85.0 ± 18.4 | 84.2 ± 19.6 | .47 | −.36 |
| RLPH | 43.3 ± 40.6 | 18.8 ± 38.6 | .06 | 1.21 | 50.0 ± 54.8 | 58.3 ± 46.6 | .39 | −.17 |
| RLEH | 53.3 ± 32.9 | 56.9 ± 37.2 | .40 | −.20 | 66.7 ± 42.7 | 83.3 ± 40.8 | .25 | −.89 |
| EF | 69.0 ± 14.2 | 51.3 ± 26.0 | .02 | .00 | 65.0 ± 30.7 | 59.2 ± 22.0 | .36 | −.05 |
| EMWB | 83.5 ± 14.6 | 79.0 ± 18.5 | .25 | −.17 | 82.0 ± 13.1 | 80.7 ± 22.3 | .45 | −.48 |
| SFUN | 81.7 ± 20.5 | 80.2 ± 22.3 | .43 | −.53 | 79.2 ± 24.6 | 81.3 ± 29.3 | .45 | −.30 |
| Pain | 73.8 ± 24.4 | 64.6 ± 23.6 | .17 | −.26 | 69.2 ± 27.5 | 79.2 ± 19.6 | .24 | −.74 |
| GH | 72.0 ± 18.0 | 75.4 ± 14.1 | .30 | −.60 | 72.5 ± 18.1 | 78.3 ± 17.8 | .29 | −.86 |
PWB = physical wellbeing, SWB = social/family wellbeing, EWB = emotional wellbeing, FWB = functional wellbeing. For SF36: PF = physical functioning, RLPH = role limitations-physical health, RLEH = role limitations-emotional health, EF = energy/fatigue, EMWB = emotional wellbeing, SFUN = social functioning, GH = general health. Higher scores on all scales indicate higher functioning.